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Aim. To investigate the ability of recombinant modiﬁed vaccinia virus Ankara (rMVA) vector to induce an immune response
against a well-tolerated self-antigen. Methods. rMVA vectors expressing diﬀerent form of α-fetoprotein (AFP) were produced and
characterized. Na¨ ıve mice were vaccinated with MVA vectors expressing the AFP antigen in either a secreted, or a membrane-
bound, or an intracellular form. The immune response was monitored by an IFNγ ELISpot assay and antibody detection. Results.
Vaccination with the membrane-associated form of AFP induced a stronger CD8+ T-cell response compared to the ones obtained
with the MVA encoding the secreted or the intracellular forms of AFP. Moreover, the vaccination with the membrane-bound AFP
elicited the production of AFP-speciﬁc antibodies. Conclusions. The AFP transmembrane form is more immunogenic. Expressing
a membrane-bound form in the context of an MVA vaccination could enhance the immunogenicity of a self-antigen.
1.Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies in the world (700, 000deaths/year) and
its incidence is increasing [1]. Therapeutic options available
include liver transplantation, surgical resection and local
ablative therapies, but the prognosis of HCC remains poor
d u et oh i g ht u m o rr e c u r r e n c er a t e s[ 2]. Thus, new strategies
are needed and immunotherapy based on stimulation of the
antitumor immune response is a promising approach [3].
AFP is a single-chain polypeptide belonging to the al-
bumin family. Secreted AFP, synthesized in the yolk sac, the
fetal liver, and the gastrointestinal tract, is the main serum
protein during the fetal development [4]. Its expression is
repressed shortly after birth and replaced by serum albumin.
However, AFP is reexpressed in 50 to 80% of HCC, whereas
its expression is low or absent in normal adult liver. Serum
AFP is used as tumor marker for HCC diagnosis and follow-
up.
SeveralvaccinationstrategiesbasedonAFPasaTAAhave
been investigated for HCC immunotherapy. Brieﬂy, AFP can
be presented as an antigen by human and murine DC and
persisting T CD8+ memory clones present in the human and
the murine repertories can recognize some peptide epitopes
derived from AFP [5–8]. In murine models, murine AFP can
function as a tumor rejection antigen in melanoma models
[9] and AFP-speciﬁc vaccination can signiﬁcantly impair the
growth of an autochthonous hepatocellular carcinoma [10].
In the two conducted clinical trials, AFP-speciﬁc CTL have
been detected in blood after AFP peptides administration
but, however, it has not been correlated to an objective
clinical response [7, 8]. This could be due to the fact that
onco-fetal antigens, including AFP, are self-tolerated mol-
eculesandthatthetumorimmuneevasionmechanismshave
to be successfully controlled to trigger an eﬃcient antitumor
response. Vaccination with altered forms of the antigen or
withthexenogeneicproteinisapossiblestrategytoovercome
the tolerance to antigens [11–13].2 Journal of Biomedicine and Biotechnology
Modiﬁed vaccinia virus Ankara (MVA) is a highly at-
tenuated vaccinia virus [14]. It has been successfully used
to raise immune response against various antigens [15, 16].
Compared to immunotherapy strategies with monoclonal
antibodies or with immunodominant peptides, vaccination
with MVA encoding a tumor antigen presents the advantage
of raising an immune response against the whole antigen.
In the context of a MVA vaccination, the primary induction
of the CTL response depends mostly on cross-presentation
suggesting that the expression of a full-length antigen
localized subcellularly should be considered during the MVA
vector design [17].
In the present study, we compare the immune response
elicited by the vaccination with a recombinant MVA vector
encoding the AFP antigen either in its native secreted form
or in modiﬁed membrane-associated or intracellular forms.
2.MaterialsandMethods
2.1. Cell Culture. Primary chicken embryo ﬁbroblasts (CEF)
were used for homologous recombination and ampliﬁcation
of recombinant vectors. CEF were prepared from chicken
embryos obtained from fertilized eggs (Lohmann, France)
previouslyincubated11daysat37◦Cinahumidatmosphere.
Embryos were dissected and treated with a TripLE Select
solution (Invitrogen) (w/v). CEF cells were maintained in
Eagle-based medium supplemented with 5% fetal bovine
serum.
2.2. Plasmid Constructions and MVA Recombinants Produc-
tion. The MVA shuttle plasmid contains a multiple-cloning
site under the control of the pH5R early-late vaccinia virus
promoter surrounded by the ﬂanking sequences of the
deletionIIIoftheMVAallowinghomologousrecombination
and a selection gene, the E. coli xanthine-guanine pho-
sphoribosyl-transferase gene (GPT gene) under the control
of the p11K7.5 promoter [18].
Full-length cDNA encoding the secreted form of
murine AFP (S-mAFP) was obtained by PCR (primers
F5 -GGCCGCGCTAGCCGCCACCATGAAGTGGATCAC-
ACCCGCTTC-3 ;R 5  -GCAGTCAGGGCCCCTGCACTC-
AGTAATACATAAACGCCCAAAGCATCACGAGTTTTG-
3 ) and digestion with NheIa n dNotIe n z y m e s( N e wE n g -
land Biolabs) on pCIneomAFP [19]. The intracellular AFP
sequence (I-mAFP) was obtained by deleting the export-
ing signal (nucleotides 1 to 54) by PCR (Primers F5 -GGC-
CGCGCTAGCCGCCACCATGAAAGCATTGCACGAAAA-
TGAGTT-3 ;R 5  -GAGCCACATCCAGGGCCAGCTTC-
3 ) and enzyme digestion. The transmembrane AFP (T-
mAFP) sequence was obtained by successive PCR and fusion
between the S-mAFP sequence and a rabies transmembrane
domain,kindlyprovidedbyDr.N.Silvestre(Transgene).The
resulting sequences, veriﬁed by sequencing, are described in
Figure 1(a) and were cloned into the corresponding sites of
the MVA shuttle plasmid.
The generation of recombinant MVAs was previously
d e s c r i b e di nd e t a i l[ 20]. Brieﬂy, CEF cells were infected
with a MVA without any inserted transgene (MVA-null)
and then transfected with the diﬀerent shuttle plasmids by
CaCl2 precipitation. Homologous recombination occurred
and recombinant MVA viruses are isolated by multiple steps
of mycophenolic acid selection. Finally, the selection marker
is eliminated by multiple passages without selection. Final
recombinantMVAviruseswerecontrolledbyPCR,ampliﬁed
inCEF,andvirusstocksweretitratedonCEFbyplaqueassay.
2.3. Western Blot Analysis. CEF cells were infected with each
MVA vector at a multiplicity of infection (MOI) of 0.2
and incubated for 48h. Cell lysate proteins were run on a
10% SDS-PAGE gel under reducing conditions and trans-
ferred onto a nitrocellulose membrane. The membrane was
incubated with a polyclonal goat anti-AFP (C-19) anti-
body (Santa Cruz) at a 1:1000 dilution or with a rabbit anti-
rabies transmembrane domain at a 1:2000 dilution. The
membrane was then washed and incubated with a secon-
dary antibody coupled with horseradish peroxidase (GE
Healthcare). Signal detection was done by enhanced chemi-
luminescence (GE Healthcare).
2.4. Animal Experiments. C3H/HeN (C3H) male mice (8
weeks) were purchased from Janvier Laboratory (France)
and were bred in the Nantes IFR 26 animal facility. All ex-
periments procedures involving animals were conducted ac-
cording to the guidelines of the French Agriculture Ministry
and were approved by the local ethical committee. Mice were
immunized three times subcutaneously (s.c.) into the ﬂank
with 5 · 107 pfu of MVA vectors at 7-day intervals. Spleen
cells from immunized mice were harvested 1 week after the
last boost.
Mice subjected to regulatory T cells depletion were in-
jected intraperitoneally (i.p.) 1 day prior the vaccination
course with 400μg of anti-CD25 antibody (PC61) purchased
from BioXCell (New Hampshire, USA).
2.5. Enzyme-Linked Immunospot Analysis. Total splenocytes
were extracted mechanically from spleen at sacriﬁce. CD8+ T
cells were isolated from spleen cells with mouse CD8a (Ly-
2) Microbeads and MS columns (Miltenyi Biotec). Speciﬁc
T-cell response was monitored on CD8+ T cells with IFNγ
ELISpot kit (Diaclone), according to the manufacturer’s
protocol. Cells, plated at a concentration of 5 × 105 cells per
well, were stimulated with 20μM of a mAFP-speciﬁc CD8+
restricted peptide (NEFGIASTL) described earlier [19], with
medium alone or with MVA-null at MOI 10 for 24h. IFNγ-
secreting cells were counted on an AID ELISpot Reader
9 (Autoimmun Diagnostika). Results are presented as the
number of IFNγ-secreting cells per million of CD8+ Tc e l l s
aftersubtractionofnonspeciﬁcsignalobtainedwithmedium
alone.
2.6. Antibody Response. Blood samples were collected on
days 0, 7, 14, and 21 during the vaccination course. Plasma
was separated by centrifugation from blood collected. A fu-
sionproteinconsistingofthenativemurineAFPandaV5tag
was used in ELISA to detect anti-AFP serological responses.
AFP open reading frame was inserted in frame with a
sequence encoding the V5 epitope in the pcDNA3.1/V5-
His vector (Invitrogen). 293 cells were transfected with theJournal of Biomedicine and Biotechnology 3
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Figure 1:GenerationofrecombinantsMVAexpressingthediﬀerentmurineAFPsequencesandevaluationofthemAFPproteinsexpression.
(a) Schematic representation of transgenes inserted into the MVA genome. The diﬀerent AFP sequences are under the control of the early-
late promoter pH5R. Δ: no insert; s: exporting sequence; tm: transmembrane domain; (b) speciﬁc detection of modiﬁed AFP proteins on
western blot by polyclonal antibody directed against the C-terminalAFP protein. Lane 1 (leftto right):mock-infected CEPcells; Lane 2: CEP
cells infected with MVA-null; Lane 3: CEP cells infected with MVA-s mAFP; Lane 4: CEP cells infected with MVA-I mAFP. Molecular weight
standards are shown in kDa on the left. The presence of the intracellular AFP protein (I mAFP) and of the secreted AFP protein (S mAFP) is
indicated (arrows). (c) Speciﬁc detection of transmembrane AFP protein on western blot by antibody directed against the transmembrane
domain. The presence of the transmembrane AFP protein (T mAFP) is indicated (arrow).
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Figure 2: AFP-speciﬁc CD8+ T-cell immune response after vaccination of C3H/HeN mice with MVA-s mAFP, MVA-I mAFP, or MVA-T
mAFP. (a) Schematic of the experimental design; (b) IFNγ ELISpot assay, CD8+ T cells from mice vaccinated with MVA-null (:n e g a t i v e
control) or MVA expressing the secreted (), the intracellular (), or the transmembrane () form of murine AFP protein were stimulated
in vitro by a speciﬁc AFP peptide. Statistical analyses were performed by the Kruskal-Wallis test.
resulting plasmid with Lipofectamine (Invitrogen) and the
AFP-V5 fusion protein was secreted in the culture super-
natant. 96-well plates were coated overnight at 4◦Cw i t ha
goat anti-V5 tag antibody (Abcam, UK) at 1μg/mL diluted
in bicarbonate coating buﬀer. Following blocking with
PBS-Tween-milk (5%) (PTM), plates were incubated
overnight at 4◦C with 100μL of supernatant containing
the AFP-V5 fusion protein. Wells were then washed three
times in PTM and incubated overnight at 4◦Cw i t hp r i -
mary mouse sera diluted serially in PTM. Wells were then
washed three times in PTM and incubated with a goat
anti-mouse IgG HRP secondary antibody (DAKO) for 2h
at room temperature. Following washings in PTM, wells
were incubated with an ABTS substrate (Roche Diagnostics,4 Journal of Biomedicine and Biotechnology
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Figure 3: Eﬀect of T reg depletion on AFP-speciﬁc and MVA-speciﬁc CD8+ T-cell immune response. (a) Schematic of the experimental
design. (b) AFP-speciﬁc CD8+ T cells from MVA-T mAFP vaccinated mice in combination with T reg depletion ()o rn o t( )w e r e
measured by IFNg ELISpot assay. (c) MVA-speciﬁc CD8+ T cells from MVA-T mAFP vaccinated mice in combination with T reg depletion
()ornot()weremeasuredbyIFNgELISpotassayafterinvitrostimulationwiththeMVA-nullvector.Statisticalanalyseswereperformed
by the Mann-Whitney test.
Germany). The colorimetric change was monitored using a
spectrophotometer.
2.7. Statistical Analysis. Statistical analyses were performed
using the non-parametric Kruskal-Wallis or Mann-Whitney
tests and GraphPad Prism software. A P value < 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Generation of Recombinants MVA Expressing AFP. The
sequences corresponding to the secreted (S mAFP), intra-
cellular (I mAFP), and transmembrane (T mAFP) forms
of the murine AFP protein were introduced in the deletion
III of the MVA genome under the control of the early-late
promoter pH5R. The recombinants MVA produced are pre-
sented in Figure 1(a). Expression of the modiﬁed AFP pro-
teins was conﬁrmed by western blot. Speciﬁc signals cor-
responding to the intracellular and to the secreted mAFP
proteins in cellular extracts isolated from CEP cells infected
either by MVA-I mAFP (Figure 1(b),l a n e1 )o rb yM V A - s
mAFP (Figure 1(b), lane 2) were detecting using a polyclonal
antibody directed against the C-terminal part of the AFP
protein. The respective sizes of these two proteins are inJournal of Biomedicine and Biotechnology 5
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Figure 4: Induction of AFP-speciﬁc antibodies after vaccination with MVA-T mAFP. (a) Schematic of the experimental design. (b) ELISA
analysis of sera from mice vaccinated with MVA-null, MVA-s mAFP, MVA-I mAFP, or MVA-T mAFP. Mean absorbances are determined
at dilutions 1:50, 1:250, and 1:1000. (c) Time course of AFP-speciﬁc antibodies titre in sera from mice (n = 3) vaccinated with MVA-T
mAFP. The absorbance is determined for a 1:50 dilution.
line with the expected size of the native mAFP protein and
with the molecular modiﬁcations achieved. As the antibody
previously used was directed against the C-terminal part of
the protein where the fusion was made, the expression of
the transmembrane form was conﬁrmed by western blot us-
ing an antibody directed against the transmembrane rabies
domain. A speciﬁc protein band was detected at a higher size
compared to the native protein in agreement to the fusion
with the supplementary domain (Figure 1(c),l a n e1 ) .
3.2. AFP-Speciﬁc CD8+ T Lymphocyte Response to MVA-T
mAFP, MVA-s mAFP, or MVA-I mAFP in Mice. Mice (n = 4)
were vaccinated with the diﬀerent recombinants MVA by
three subcutaneous injections one week apart (Figure 2(b)).
One week after the last immunization, the speciﬁc CD8+
T-cell response was measured in an interferon gamma
ELISpot assay, with the H-2k AFP peptide NEFGIASTL,
as described previously [19]. As shown in Figure 2(b) and
as expected, no speciﬁc response was detected in mice
vaccinated with the parental vector MVA-null. Surprisingly,
no signiﬁcant increase in the number of spots was observed
in mice vaccinated either with MVA-s mAFP or with MVA-I
mAFP. In contrast, MVA-T mAFP-vaccinated mice displayed
a signiﬁcantly higher number of IFN-γ-producing cells
compared to mice vaccinated with the other MVA vectors.
Thus, in the context of AFP vaccination by an MVA vector,
the transmembrane form elicits a higher CD8+ T-cell im-
mune response in C3H/HeN-vaccinated mice.
3.3. The AFP-Speciﬁc Immune Response Is Not Modulated by
the CD25+ TC e l l s .Populations of regulatory T cells could
impair the immune response against a self-antigen such as6 Journal of Biomedicine and Biotechnology
AFP [21]. To address this possibility, groups of mice were
vaccinated with the MVA-T mAFP vector, with or without
an injection of 400μg of PC61 anti-CD25 monoclonal
antibodythedaybeforetheﬁrstvaccination(Figure 3(a)).At
sacriﬁce, CD4+ CD25+ T-cell depletion was veriﬁed by FACS
analysis (data not shown) and the CD8+ T-cell response was
compared in splenocytes prepared from the two groups by
IFNgELISpotassay.Asingleinjectionofanti-CD25antibody
did not enhance signiﬁcantly the AFP-speciﬁc CD8+ T-
cell immune response (Figure 3(b)). In contrast, the T reg
depletion has an impact on the immune response against the
vector (Figure 3(c)). In fact, the antibody injection resulted
in a signiﬁcantly higher number of IFN-γ-producing CD8+
TcellsafterMVArestimulationconﬁrmingthatthedepletion
did occur.
3.4. Vaccination with MVA-T mAFP Elicits the Production of
Anti-AFP Antibodies. To monitor the AFP-speciﬁc humoral
response elicited by the vaccinations with the MVA recom-
binant vectors, mice (n = 3) were vaccinated either with the
MVA AFP viruses or with the MVA-null, by three injections
one week apart and sacriﬁced one week after. Sera were
collected prior to each vaccination and at sacriﬁce. The
serological response was assessed by ELISA as described in
the Material and Methods section. The presence at sacriﬁce
ofcirculatingantibodiesdirectedagainsttheAFPproteinwas
analyzed in mice vaccinated with the four diﬀerent MVAs
(Figure 4(b)). No AFP-speciﬁc antibody could be detected
in the sera of mice vaccinated with MVA-null, or MVA-
s mAFP or MVA-I mAFP, even at the minimal dilution
(1:50). In contrast, vaccination with MVA-T mAFP elicited
a signiﬁcantly stronger speciﬁc antibody response. The time
course of AFP-speciﬁc antibody titer was assessed during the
vaccination protocol (Figure 4(c)). Repeated immunizations
(at day 0, day 7, and day 14) with MVA-T mAFP led to the
productionofAFP-speciﬁcantibodieswhichwasmaximalby
day 14 and remained stable at day 21.
4. Discussion
Tolerance to tumor-associated antigen is profound, therefore
strenuous immune modulation is required to overcome it
and achieve meaningful response. In this paper, we assessed
the ability of MVA to induce an immune response against
the self-antigen α-fetoprotein (AFP), and we compared the
immunogenicity of diﬀerent forms of this antigen after
vaccination in na¨ ıve mice. Three vaccines were generated
to encode recombinant AFP that was either secreted or
membrane-bound or cytosolic. Comparable strategies tar-
geting antigen to speciﬁc subcellular compartments have
been shown to eﬃciently modulate the speciﬁc immune
response elicited [17]. The correct expression of the recom-
binant AFP forms by the MVA vectors was ﬁrst conﬁrmed.
Thevaccinationprotocolconsistedinthreesubcutaneousin-
jections one week apart and one week later, both the cellular-
speciﬁcCD8+ T-cellresponseandthehumoralresponsewere
monitored. Expression of a cytosolic form of AFP failed to
raise a strong immune response as what has been shown
for a soluble cytosolic fragment of the Her-2 protein which
is promptly degraded by the proteasome [22]. Vaccination
with the transmembrane form of AFP induced a stronger
CD8+ T-cell response compared to the ones obtained with
the MVA encoding the secreted and the intracellular forms
of AFP. Since the number of speciﬁc spots was limited, we
evaluated the eﬀect of a T reg depletion on the immune
response obtained and we concluded that the AFP-speciﬁc
CD8+ response was not modulated by the CD25+ Tc e l l
population during a MVA-T mAFP vaccination protocol.
Finally, the vaccination with the transmembrane form of
the antigen leads to the production of antibodies directed
againstAFP.Previously,vaccinationwithanMVAencodinga
modiﬁed membrane-associated form of the epithelial tumor
antigen H23, aberrantly expressed in breast cancer, has been
shown to allow the production of elevated levels of speciﬁc
antibodies in vaccinated animals [23, 24]. The diﬃculty to
raise a signiﬁcant immune response against AFP compared
to other TAA could be due to the fact that this self-antigen is
produced by the liver, which is known to constitute a speciﬁc
tolerogenic environment [25].
In conclusion, we demonstrate that the secreted and the
intracellularAFPantigensexpressedfromMVAarelesseﬀec-
tive immunogens than their transmembrane counterpart.
Vaccination with a membrane-bound form of a self-antigen,
combined with other strategies, involving stimulation with
cytokines (IL2, IL12, GM-CSF) [26, 27] could represent
a promising strategy to enhance immunogenicity in the
context of MVA vaccination.
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